Press release
Non-Hodgkin Lymphoma Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Non-Hodgkin Lymphoma Overview
Non-Hodgkin's lymphoma (NHL) is a cancer of the lymphatic system. It occurs when tumors develop from the lymphocytes. Alymphocyte is a type of white blood cell. NHL is more common than Hodgkin's lymphoma. The main difference between Hodgkin's lymphoma and NHL is the presence of a type of abnormal cell called the Reed-Sternberg cell. This type of abnormal cell is only present in Hodgkin's lymphoma.
"Non-Hodgkin Lymphoma Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma Market.
The Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Non-Hodgkin Lymphoma Pipeline Report: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years. Non-Hodgkin Lymphoma Key players such as - Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Autolus, Genor Biopharma, AbbVie, Genmab, AstraZeneca, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others, are developing therapies for the Non-Hodgkin Lymphoma treatment
• Non-Hodgkin Lymphoma Emerging therapies such as - HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, AUTO4, GB226, Epcoritamab, Capivasertib, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others are expected to have a significant impact on the Non-Hodgkin Lymphoma market in the coming years.
• Novartis initiated a a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy
Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment
• Non-Hodgkin Lymphoma Assessment by Product Type
• Non-Hodgkin Lymphoma By Stage and Product Type
• Non-Hodgkin Lymphoma Assessment by Route of Administration
• Non-Hodgkin Lymphoma By Stage and Route of Administration
• Non-Hodgkin Lymphoma Assessment by Molecule Type
• Non-Hodgkin Lymphoma by Stage and Molecule Type
DelveInsight's Non-Hodgkin Lymphoma Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:
• HRS-3738: Jiangsu Hengrui Medicine
• PCLX-001: Pacylex Pharmaceuticals
• ZN-d5: Zentera Therapeutics
• TC-110: TCR2 Therapeutics
• AB-101: Artiva Biotherapeutics
• AUTO4: Autolus
• GB226: Genor Biopharma
• Epcoritamab: AbbVie/ Genmab
• Capivasertib: AstraZeneca
• LOXO-305: Loxo Oncology
• AB-205: Angiocrine Bioscience
• Venetoclax: AbbVie
• Tisagenlecleucel: Novartis
Get a Free Sample PDF Report to know more about Non-Hodgkin Lymphoma Pipeline Assessment- https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Non-Hodgkin Lymphoma Pipeline Analysis:
The Non-Hodgkin Lymphoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Non-Hodgkin Lymphoma treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
• Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Non-Hodgkin Lymphoma product details are provided in the report. Download the Non-Hodgkin Lymphoma pipeline report to learn more about the emerging Non-Hodgkin Lymphoma therapies at:
https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Non-Hodgkin Lymphoma Pipeline Market Drivers
• Increasing prevalence
• Ongoing and increased R&D activity
• Demand for innovative drugs and novel therapies
Non-Hodgkin Lymphoma Pipeline Market Barriers
• High cost of treatment
• Complications related to the drugs
Scope of Non-Hodgkin Lymphoma Pipeline Drug Insight
• Coverage: Global
• Key Non-Hodgkin Lymphoma Companies: Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Autolus, Genor Biopharma, AbbVie, Genmab, AstraZeneca, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others
• Key Non-Hodgkin Lymphoma Therapies: HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, AUTO4, GB226, Epcoritamab, Capivasertib, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others
• Non-Hodgkin Lymphoma Therapeutic Assessment: Non-Hodgkin Lymphoma current marketed and Non-Hodgkin Lymphoma emerging therapies
• Non-Hodgkin Lymphoma Market Dynamics: Non-Hodgkin Lymphoma market drivers and Non-Hodgkin Lymphoma market barriers
Request for Sample PDF Report for Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Non-Hodgkin Lymphoma Report Introduction
2 Non-Hodgkin Lymphoma Executive Summary
3 Non-Hodgkin Lymphoma Overview
4 Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment
5 Non-Hodgkin Lymphoma Pipeline Therapeutics
6 Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)
7 Non-Hodgkin Lymphoma Mid Stage Products (Phase II)
8 Non-Hodgkin Lymphoma Early Stage Products (Phase I)
9 Non-Hodgkin Lymphoma Preclinical Stage Products
10 Non-Hodgkin Lymphoma Therapeutics Assessment
11 Non-Hodgkin Lymphoma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Non-Hodgkin Lymphoma Key Companies
14 Non-Hodgkin Lymphoma Key Products
15 Non-Hodgkin Lymphoma Unmet Needs
16 Non-Hodgkin Lymphoma Market Drivers and Barriers
17 Non-Hodgkin Lymphoma Future Perspectives and Conclusion
18 Non-Hodgkin Lymphoma Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Non-Hodgkin Lymphoma drugs and therapies- https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Non-Hodgkin Lymphoma Market https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Hodgkin Lymphoma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Non-Hodgkin Lymphoma Epidemiology https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Hodgkin Lymphoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Hodgkin Lymphoma Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2890894 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Hodgkin
Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph
According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%.
Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/
Key Highlights
Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70…
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth…
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The non hodgkin…
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067
Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides…
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)…
